A biotech startup developing T-cell and NK-cell therapies derived from low-immunogenicity iPS cells. It aims to provide new treatments for solid tumors and autoimmune diseases, contributing to the treatment of previously difficult-to-treat intractable diseases.
Shinobi Therapeutics（Shinobi、本社：米国カリフォルニア州サンフランシスコ、日本法人：京都府京都市）は51百万ドルのシリーズAファイナンスを完了いたしました。このラウンドには、EQT Life Sciences、Eight ...
2023年２月14日 サイアス株式会社 サイアス株式会社が三角株式交換により米国サイアス・インクを親会社とする組織再編を実施 サイアス株式会社（京都市左京区、代表取締役 等泰道、五ノ坪良輔） は、米国...
2022年1２月28日 サイアス株式会社 サイアス、約9.5 億円の AMED 委託事業に採択 iPS 細胞由来キラーT細胞療法の世界に先駆けた治験実施を目指す サイアス株式会社（京都市左京区、代表取締役 等泰道・...
2022年12月20日 サイアス株式会社 国立大学法人京都大学iPS細胞研究所 公益財団法人京都大学iPS細胞研究財団 同種iPS細胞由来CAR-NK細胞の治験薬製造に係る共同研究契約及びデータ・特許の独占的な実施...
2022年2月28日 各 位 サイアス株式会社 サイアス、Eight Roads Ventures Japan及びF-Prime Capital Partnersを新規投資家とし、総額21.3億円の資金調達完了、米国展開へ サイアス株式会社（京都府京都市...
C&H Inc. is engaged in the research and production of cannabinoids and hemp. Based in the SME Support Laboratory within Doshisha University, we are conducting advanced research and development, while also collaborating with Doshisha Women’s College. Through science-based innovation, we explore new possibilities to support both mental and physical wellness.
A startup building on ATR’s research achievements to develop products and services applying neuroscience, speech, and sensor technologies. It supports the dissemination of telecommunications technologies and talent development, accelerating the social implementation and industrial application of research outcomes.
ScienceEdge is a startup developing optical measurement instruments powered by cutting-edge laser technology and advanced microscopy engineering. Our flagship product is the thermoreflectance microscope — the world’s first commercially available system of its kind. This innovative analytical microscope enables nanoscale to microscale measurement of thermal conductivity, and is attracting strong attention from researchers and engineers working to solve the growing heat challenges in AI semiconductor development. Our vision is “Trusted Microscopy. Unbridled Pioneering.” We strive to be a trusted global brand while continuously pursuing bold, unconstrained innovation.
A startup developing allogeneic T-cell therapies from pluripotent stem cells to provide novel treatments for advanced and recurrent cancers and immune-related diseases. Aiming to deliver the potential for a cure to diseases that were previously difficult to treat.